Urological malignancies and the proteomic-genomic interface.

Abstract excerpt

The urological malignancies, renal, bladder and prostate cancer, account for approximately 16% of all cancer cases. Unfortunately 5-year survival rates are relatively poor, largely a result of many cases not being diagnosed before the tumour has metastasised. There is a clear need for the identification of markers which will allow earlier detection of disease, and predict prognosis and response to therapy. In...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genome
• Share to Mutation
• Share to Prostatic Neoplasms